Important matters:
Conoa-B (02162) reached a licensing agreement for marketing registration and commercialization of spoxibizumab injections in 18 countries and regions including Southeast Asia and Central Asia
Shisi Pharmaceutical Group (02005): Diltiazem hydrochloride tablets (30mg) have obtained approval from the State Drug Administration to pass the consistent evaluation of the quality and efficacy of generic drugs
Brain Aurora-B (06681): Research results on adaptive cognitive training for schizophrenia were published in “NPJ Digital Medicine”
Peger Biopharmaceutical-B (02565) signs material transfer agreement with SN BioScience to promote long-term development of three innovative peptide drug candidates for next-generation metabolic diseases, including APGP6
China Gold International (02099) was selected for Hang Seng Growth Index and Hang Seng Hong Kong Stock Connect Central Enterprise Quality Index
Ketuo Co., Ltd. (02272) plans to implement full circulation of H shares
Extraordinary Leadership (00933): Further acquisition of a total of 17.253,500 shares of Li Ning Company
Honghua Group (00196) subsidiary signed a 600 million yuan drilling rig sales agreement with Middle Eastern customers to provide several sets of large-scale drilling rig equipment
Dacheng Biochemical Technology (00809): Boiler refurbishment project completed and civil engineering for Coenzyme Q10 project started
Buyback/increase or decrease holdings:
Tencent Holdings (00700) spent about HK$100 million to repurchase 229,000 shares on September 2
Ideal Automobile-W (02015) spent HK$705.762 million to buy back 1,561,900 shares on September 2
Gizhijia-W (02590) spent HK$388.611 million to repurchase 4.4 million shares on September 2
Mingchuang Premium (09896) spent HK$31.8606 million to buy back 1,704,800 shares on September 2
Sansheng Pharmaceutical (01530) spent HK$235.85 million to buy back 1.5 million shares on September 2